Substantial harm associated with failure of chronic paediatric central venous access devices
- PMID: 28687683
- PMCID: PMC5534914
- DOI: 10.1136/bcr-2016-218757
Substantial harm associated with failure of chronic paediatric central venous access devices
Abstract
Central venous access devices (CVADs) form an important component of modern paediatric healthcare, especially for children with chronic health conditions such as cancer or gastrointestinal disorders. However device failure and complications rates are high.Over 2½ years, a child requiring parenteral nutrition and associated vascular access dependency due to 'short gut syndrome' (intestinal failure secondary to gastroschisis and resultant significant bowel resection) had ten CVADs inserted, with ninesubsequently failing. This resulted in multiple anaesthetics, invasive procedures, injuries, vascular depletion, interrupted nutrition, delayed treatment and substantial healthcare costs. A conservative estimate of the institutional costs for each insertion, or rewiring, of her tunnelled CVAD was $A10 253 (2016 Australian dollars).These complications and device failures had significant negative impact on the child and her family. Considering the commonality of conditions requiring prolonged vascular access, these failures also have a significant impact on international health service costs.
Keywords: Congenital Disorders; Infection Control In Hospital; Intravenous / Infusion Nursing.
© BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: Griffith University has received unrestricted investigator initiated research grants to support research projects undertaken by AJU from product manufacturers (3M, Adhezion, Angiodynamics, B. Braun, Centurion Medical Products). Griffith University has received consultancy payments on AJU’s behalf from manufacturers (3M, BD). Griffith University has received unrestricted investigator initiated research and education grants to support projects undertaken by TK from product manufacturers (3M, Adhezion, Angiodynamics, Baxter, Centurion Medical Products). Griffith University has received consultancy payments on TK’s behalf from manufacturers (BD and Angiodynamics). Griffith University has received unrestricted investigator initiated research or educational grants on CRM’s behalf from product manufacturers (3M, Adhezion, Angiodynamics; B. Braun, Becton Dickinson; Carefusion; Centurion Medical Products; Entrotech, Smiths Medical, Teleflex). Griffith University has received consultancy payments on CRM’s behalf from manufacturers (3M, B. Braun, BD, ResQDevices, Smiths Medical). Griffith University has received an unrestricted investigator initiated research or educational grant on MC’s behalf from manufacturers (Baxter, BD).
Similar articles
-
Central venous access device-related infections in patients with haemophilia.J Paediatr Child Health. 2013 Mar;49(3):242-5. doi: 10.1111/jpc.12112. Epub 2013 Feb 26. J Paediatr Child Health. 2013. PMID: 23438133
-
Central venous catheter repair is not associated with an increased risk of central line infection or colonization in intestinal failure pediatric patients.J Pediatr Surg. 2016 Mar;51(3):395-7. doi: 10.1016/j.jpedsurg.2015.08.003. Epub 2015 Aug 8. J Pediatr Surg. 2016. PMID: 26362005
-
Repair of central venous access devices in intestinal failure patients is safe and cost-effective: A retrospective single centre cohort study.Clin Nutr. 2021 Jun;40(6):4263-4266. doi: 10.1016/j.clnu.2021.01.024. Epub 2021 Jan 27. Clin Nutr. 2021. PMID: 33551216
-
Infection of totally implantable venous access devices: A review of the literature.J Vasc Access. 2018 May;19(3):230-242. doi: 10.1177/1129729818758999. Epub 2018 Mar 7. J Vasc Access. 2018. PMID: 29512430 Review.
-
The use of central venous lines in the treatment of chronically ill children.Adv Clin Exp Med. 2014 Nov-Dec;23(6):1001-9. doi: 10.17219/acem/37359. Adv Clin Exp Med. 2014. PMID: 25618129 Review.
Cited by
-
Pediatric central venous access devices: practice, performance, and costs.Pediatr Res. 2022 Nov;92(5):1381-1390. doi: 10.1038/s41390-022-01977-1. Epub 2022 Feb 8. Pediatr Res. 2022. PMID: 35136199 Free PMC article.
-
Unexpected tunnelled central venous access demise: a single institutional study from the UK.Pediatr Surg Int. 2021 Jan;37(1):109-117. doi: 10.1007/s00383-020-04771-4. Epub 2020 Nov 7. Pediatr Surg Int. 2021. PMID: 33159555
-
Central venous access device adverse events in pediatric patients with cancer: a systematic review and meta-analysis.Support Care Cancer. 2024 Sep 16;32(10):662. doi: 10.1007/s00520-024-08853-0. Support Care Cancer. 2024. PMID: 39283363 Free PMC article.
References
-
- Australian Institute of Health and Welfare. Admitted patient care 2013-14: Australian hospital statistics Australian Institute of Health and Welfare. Canberra: Australian Government, 2015.
-
- World Health Organization. Preventing bloodstream infections from central line venous catheters 2012. (accessed 12 nov 2012).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources